Healthcare provider profile · identity verified

Mark Schulein, MD

Family Practice · LIVINGSTON, MT · NPI 1992892509

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	167	45
Lisinopril	Lisinopril	125	32
Levothyroxine Sodium	Levothyroxine Sodium	101	17
Metoprolol Succinate	Metoprolol Succinate	95	21
Omeprazole	Omeprazole	94	17
Gabapentin	Gabapentin	89	21
Losartan Potassium	Losartan Potassium	88	26
Amlodipine Besylate	Amlodipine Besylate	75	20
Metformin Hcl	Metformin Hcl	69	18
Tamsulosin Hcl	Tamsulosin Hcl	65	17
Pantoprazole Sodium	Pantoprazole Sodium	59	suppressed
Trazodone Hcl	Trazodone Hcl	58	16
Oxycodone Hcl	Oxycodone Hcl	57	16
Escitalopram Oxalate	Escitalopram Oxalate	55	11
Furosemide	Furosemide	55	11
Fluticasone Propionate	Fluticasone Propionate	54	12
Risperidone	Risperidone	53	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	51	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	51	suppressed
Pregabalin	Pregabalin	51	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	47	22
Chlorthalidone	Chlorthalidone	47	16
Famotidine	Famotidine	42	suppressed
Potassium Chloride	Potassium Chloride	42	suppressed
Ozempic	Semaglutide	41	suppressed
Mirtazapine	Mirtazapine	39	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	38	suppressed
Montelukast Sodium	Montelukast Sodium	37	suppressed
Duloxetine Hcl	Duloxetine Hcl	35	suppressed
Prednisone	Prednisone	35	12
Baclofen	Baclofen	34	suppressed
Clonidine Hcl	Clonidine Hcl	33	suppressed
Hydrochlorothiazide	Hydrochlorothiazide	33	11
Xarelto	Rivaroxaban	32	suppressed
Breo Ellipta	Fluticasone/Vilanterol	29	suppressed
Rosuvastatin Calcium	Rosuvastatin Calcium	28	suppressed
Simvastatin	Simvastatin	28	suppressed
Bupropion Xl	Bupropion Hcl	27	suppressed
Clonazepam	Clonazepam	27	suppressed
Jardiance	Empagliflozin	27	suppressed
Stiolto Respimat	Tiotropium Br/Olodaterol Hcl	27	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	26	suppressed
Eliquis	Apixaban	25	suppressed
Olanzapine	Olanzapine	25	suppressed
Sertraline Hcl	Sertraline Hcl	25	suppressed
Methylphenidate Hcl	Methylphenidate Hcl	24	suppressed
Propranolol Hcl	Propranolol Hcl	24	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	22	suppressed
Allopurinol	Allopurinol	21	suppressed
Aripiprazole	Aripiprazole	21	suppressed
Finasteride	Finasteride	21	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	20	suppressed
Torsemide	Torsemide	20	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	19	suppressed
Tramadol Hcl	Tramadol Hcl	19	suppressed
Carvedilol	Carvedilol	18	suppressed
Loperamide	Loperamide Hcl	18	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	18	suppressed
Azithromycin	Azithromycin	17	suppressed
Divalproex Sodium Er	Divalproex Sodium	17	suppressed
Imipramine Hcl	Imipramine Hcl	17	suppressed
Donepezil Hcl	Donepezil Hcl	16	suppressed
Ezetimibe	Ezetimibe	16	suppressed
Lorazepam	Lorazepam	16	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	15	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	15	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	15	suppressed
Ventolin Hfa	Albuterol Sulfate	15	suppressed
Alprazolam	Alprazolam	14	suppressed
Ibuprofen	Ibuprofen	14	suppressed
Metformin Hcl Er	Metformin Hcl	14	suppressed
Spironolactone	Spironolactone	14	suppressed
Prazosin Hcl	Prazosin Hcl	13	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	13	suppressed
Cilostazol	Cilostazol	12	suppressed
Lovastatin	Lovastatin	12	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	11	suppressed
Emgality Pen	Galcanezumab-Gnlm	11	suppressed
Lithium Carbonate Er	Lithium Carbonate	11	suppressed
Promethazine Hcl	Promethazine Hcl	11	suppressed
Rybelsus	Semaglutide	11	suppressed
Spiriva Handihaler	Tiotropium Bromide	11	suppressed
Verapamil Er	Verapamil Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error